Literature DB >> 20471562

Perivascular epithelioid cell tumor of abdominal origin.

David Cantú de León1, Delia Pérez-Montiel, Arfy Bandera, Carlos Villegas, Esther Gonzalez-Conde, José Chanona Vilchis.   

Abstract

Perivascular epithelioid tumor is not a common disease; therefore, large series are not available in the literature, and most are case reports. Histologic characteristics of these neoplasms are positivity to melanogenic (HMB-45) and muscle stains. All these neoplasms have the characteristic perivascular epithelioid cell or "PEC," but the term myomelanocyte tumor has been proposed because of the immunohistochemistry expression. Females are affected more commonly than males. The uterus seems to be one of the most common organs affected. Its clinical behavior is uncertain, and standard treatment has not been established as well as criteria for malignancy. We report 3 cases of abdominal PEComa, 1 of them with benign clinical outcome and 2 with an aggressive behavior.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471562     DOI: 10.1016/j.anndiagpath.2010.02.007

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  3 in total

1.  PEComa of the terminal ileum mesentery as a secondary tumour in an adult survivor of embryonal rhabdomyosarcoma.

Authors:  H Hasan; A F Howard; A H Alassiri; T L Ng; G McGregor; K Goddard
Journal:  Curr Oncol       Date:  2015-10       Impact factor: 3.677

2.  "Malignant" perivascular epithelioid cell neoplasm: risk stratification and treatment strategies.

Authors:  Jonathan S Bleeker; J Fernando Quevedo; Andrew L Folpe
Journal:  Sarcoma       Date:  2012-04-26

3.  Retroperitoneal perivascular epithelioid cell tumours: A case report and review of literature.

Authors:  Zisis Touloumis; Niki Giannakou; Christos Sioros; Argiro Trigka; Maria Cheilakea; Nikoletta Dimitriou; John Griniatsos
Journal:  World J Clin Cases       Date:  2019-11-06       Impact factor: 1.337

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.